After a harsh internal review on Tuesday, there was very little hope of PTC Therapeutics' (PTCT) Duchenne muscular dystrophy drug Translarna being recommended for approval by the panel of outside experts convened by the FDA on September 28, 2017.
from RTT - Biotech http://ift.tt/2x1rv0y
via IFTTT
No comments:
Post a Comment